NasdaqGS - Delayed Quote USD

Inhibrx Biosciences, Inc. (INBX)

Compare
13.83 -0.50 (-3.49%)
At close: November 15 at 4:00 PM EST
13.83 +0.03 (+0.22%)
After hours: November 15 at 4:00 PM EST
Advanced Chart
Loading Chart for INBX
DELL
  • Previous Close 14.33
  • Open 14.33
  • Bid 13.57 x 100
  • Ask 13.96 x 100
  • Day's Range 12.25 - 14.77
  • 52 Week Range 10.80 - 18.95
  • Volume 178,264
  • Avg. Volume 93,892
  • Market Cap (intraday) 200.202M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 0.12
  • EPS (TTM) 118.84
  • Earnings Date Nov 14, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

inhibrx.com

166

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Inhibrx Biosciences, Inc.

Recent News: INBX

View More
View More

Performance Overview: INBX

Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

INBX
25.04%
S&P 500
10.95%

1-Year Return

INBX
25.04%
S&P 500
10.95%

3-Year Return

INBX
25.04%
S&P 500
10.95%

5-Year Return

INBX
25.04%
S&P 500
10.95%

Compare To: INBX

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

INBX
Inhibrx Biosciences, Inc.
13.83
-3.49%
Mkt Cap 200.202M
Industry Biotechnology
LBPH
Longboard Pharmaceuticals, Inc.
59.69
-0.08%
Mkt Cap 2.331B
Industry Biotechnology
DYN
Dyne Therapeutics, Inc.
28.39
-6.33%
Mkt Cap 2.889B
Industry Biotechnology
ALMS
Alumis Inc.
8.85
-5.95%
Mkt Cap 481.469M
Industry Biotechnology
MIRM
Mirum Pharmaceuticals, Inc.
44.50
-3.80%
Mkt Cap 2.136B
Industry Biotechnology
MLYS
Mineralys Therapeutics, Inc.
11.48
-5.67%
Mkt Cap 571.345M
Industry Biotechnology
MRVI
Maravai LifeSciences Holdings, Inc.
4.4200
-15.00%
Mkt Cap 1.116B
Industry Biotechnology
BDRX
Biodexa Pharmaceuticals Plc
3.6200
-25.90%
Mkt Cap 2.103M
Industry Biotechnology
CRNX
Crinetics Pharmaceuticals, Inc.
54.72
-8.28%
Mkt Cap 5.075B
Industry Biotechnology
KYMR
Kymera Therapeutics, Inc.
41.96
-8.67%
Mkt Cap 2.718B
Industry Biotechnology
ROIV
Roivant Sciences Ltd.
11.20
-3.78%
Mkt Cap 8.153B
Industry Biotechnology

Statistics: INBX

View More

Valuation Measures

Annual
As of 11/15/2024

  • Market Cap

    200.20M

  • Enterprise Value

    -24.49M

  • Trailing P/E

    0.12

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    118.67

  • Price/Book (mrq)

    0.91

  • Enterprise Value/Revenue

    16.98

  • Enterprise Value/EBITDA

    0.02

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    101,974.22%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.69M

  • Net Income Avi to Common (ttm)

    1.72B

  • Diluted EPS (ttm)

    118.84

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    226.86M

  • Total Debt/Equity (mrq)

    0.99%

  • Levered Free Cash Flow (ttm)

    --

View More

Company Insights: INBX

People Also Watch

KROS Keros Therapeutics, Inc.
56.62
-6.18%
 
KYMR Kymera Therapeutics, Inc.
41.96
-8.67%
 
ITOS iTeos Therapeutics, Inc.
8.23
-2.72%
 
HRMY Harmony Biosciences Holdings, Inc.
33.22
+0.65%
 
ZNTL Zentalis Pharmaceuticals, Inc.
3.4700
-12.15%
 
FDMT 4D Molecular Therapeutics, Inc.
8.83
+10.10%
 
PCVX Vaxcyte, Inc.
86.83
-6.31%
 
ORIC ORIC Pharmaceuticals, Inc.
8.50
-3.74%
 
NRIX Nurix Therapeutics, Inc.
22.92
-14.67%
 
FHTX Foghorn Therapeutics Inc.
8.01
-8.98%
 
PMVP PMV Pharmaceuticals, Inc.
1.6100
+0.62%
 
GBIO Generation Bio Co.
1.5400
-8.33%
 
ALXO ALX Oncology Holdings Inc.
1.2900
-3.01%
 
INZY Inozyme Pharma, Inc.
3.1250
-8.89%
 
OLMA Olema Pharmaceuticals, Inc.
9.17
-9.21%
 
IDYA IDEAYA Biosciences, Inc.
26.64
-9.60%